# Goldenrod Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/goldenrod-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Houston, US
- Website: www.goldenrodtx.com
- Total disclosed funding: $3.3M
- Latest round: Seed (May 26, 2026)
- Investors on record: 2

## About

Founded in 2020 and headquartered in Texas, US, Goldenrod Therapeutics, Inc. specializes in the development of PDE4 inhibitors aimed at treating severe neurological disorders. In June 2026, Goldenrod Therapeutics raised USD 6.5 million in seed funding led by Ataxia Ventures, with participation from Fannin. This round was a larger part of USD 6.5 million seed and grant funding. As of July 2026, Dev Chatterjee is the CEO of the company.

Goldenrod Therapeutics has recently completed a USD 6.5 mn Seed preferred stock round, reflecting investor interest in its drug development initiatives. The company's revenue-generation strategy is expected to involve partnerships with healthcare providers and pharmaceutical distributors, as well as direct-to-consumer sales contingent upon regulatory approvals. The pricing for these premium products is designed to ensure sustainable revenue generation as the company advances its therapeutic pipeline toward commercialization.

The company plans to use June 2026 funds to extend its manufacturing, formulation optimization and IND-enabling studies, along with funding a Phase I study in its beachhead therapeutic indication in Friedreich’s Ataxia (FA), a rare and progressive neurodegenerative disease.

## Funding rounds

- Seed, May 26, 2026, $3.3M — Fannin, Ataxia Ventures

## Investors

- Fannin (https://capitalatlas.ai/funds/fannin) — Seed
- Ataxia Ventures — Seed